Astrazeneca Pharma India Ltd
Astrazeneca Pharma India Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹729Cr
- Net profit
- ₹62Cr
- Margin
- 13.1%
Guidance rank: #21 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Astrazeneca Pharma India Ltd Q2 FY27 key numbers
- Revenue
- Revenue from operations for the quarter ended 30 September 2026 was Rs 7,291.0 million.
As stated in Astrazeneca Pharma India Ltd's Q2 FY27 results statement · published 6 Nov 2026. Reported figures, not investment advice.
Based on Astrazeneca Pharma India Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the quarter ended 30 September 2026 was Rs 7,291.0 million.
From Astrazeneca Pharma India Ltd's Q2 FY27 earnings-call transcript · updated 6 Nov 2026.
How did Astrazeneca Pharma India's revenue grow in the September 2026 quarter?
- Revenue from operations for the quarter ended 30 September 2026 was Rs 7,291.0 million.
- Revenue from operations for the quarter ended 30 September 2025 was Rs 5,590.9 million.
- Year-on-year revenue growth for the quarter: Rs 7,291.0 million vs Rs 5,590.9 million, approximately 30.5% increase.
2 more points from Astrazeneca Pharma India Ltd's call on revenue
Create a free account to keep reading this call
What happened to Astrazeneca Pharma India's margins in Q2 FY27?
See what Astrazeneca Pharma India Ltd said on profitability & margins — free account, 30 seconds.
What capex is Astrazeneca Pharma India planning?
See what Astrazeneca Pharma India Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Astrazeneca Pharma India raising money or cutting debt?
See what Astrazeneca Pharma India Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Astrazeneca Pharma India's order book?
See what Astrazeneca Pharma India Ltd said on order book & pipeline — free account, 30 seconds.
Astrazeneca Pharma India Ltd — Quarterly revenue & net profit
Astrazeneca Pharma India Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 729 |
| Operating profit (EBITDA) | 96 |
| Operating margin | 13.1% |
| Profit before tax | 88 |
| Net profit (PAT) | 62 |
| EPS (₹) | 24.93 |
Source: Astrazeneca Pharma India Ltd's results filing to NSE (standalone), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹729 Cr, net profit ₹62 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Astrazeneca Phar's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Kilitch Drugs (Q2 FY27)
14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- NGL Fine Chem (Q2 FY27)
Consolidated: ₹15,870.73 lakhs . Key results statement takeaways from NGL Fine Chem Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Mangalam Drugs (Q2 FY27)
59% growth. Key results statement takeaways from Mangalam Drugs and Organics Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Cohance Lifesciences Ltd (Q2 FY27)
Q2 FY27 revenue: INR 4,766 Mn, down 14.2% YoY (Page 8, 9) . Key investor presentation takeaways from Cohance Lifesciences Ltd's Q2 FY27 investor presentation —
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Astrazeneca Pharma India Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Astrazeneca Pharma India Ltd Q2 FY27 results?
Revenue from operations for the quarter ended 30 September 2026 was Rs 7,291.0 million.
What is Astrazeneca Pharma India Ltd share price analysis?
Astrazeneca Pharma India Ltd currently shows a neutral. The stock trades at a P/E of 91.8 with a market cap of ₹15,934 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Astrazeneca Pharma India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.